Clearmind Medicine(CMND.US)

Company Encyclopedia
View More
name
Clearmind Medicine
CMND.US
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd.
4.707 T
CMND.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Clearmind Medicine Reports Positive Phase I/IIa Results for CMND-100 in Alcohol Use Disorder Trial

    Clearmind Medicine Inc. reported positive results from its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, conducted at prestigious institutions like Yale and Johns Hopkins, has shown favorable safety and tolerability with no serious adverse events. The Data and Safety Monitoring Board approved the trial's continuation after an interim review. Enrollment and dosing for the second cohort are complete, with more data expected in the future.

    Reuters·
    US
    CMND
    -4.62%
    Reuters·
    US
    CMND
    -4.62%

    Clearmind Medicine reflects on transformative 2025 with key advancements, global reach; Focus on CMND-100 for AUD. Nasdaq: CMND (FSE: CWY0) .

    In Vancouver, Canada, on December 24, 2025, Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) announced its achievements over the year in developing innovative neuroplastogen-derived therapeutics. The company has been focusing on addressing prevalent health issues with limited treatment options. One of its key milestones includes the advancement of CMND-100, the leading candidate for treating Alcohol Use Disorder (AUD).

    Unusual Whales·
    US
    CMND
    -4.62%
    Unusual Whales·
    US
    CMND
    -4.62%

    Clearmind Medicine Advances Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

    Clearmind Medicine Inc. announced progress in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder. The trial, conducted at Yale and Johns Hopkins, completed enrollment and dosing for the first two cohorts with positive safety results and no serious adverse events. The DSMB approved the continuation of the study. Further clinical data will be released as the trial progresses.

    Reuters·
    US
    CMND
    -4.62%
    Reuters·
    US
    CMND
    -4.62%

    Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth | CMND Stock News

    Clearmind Medicine Inc. reflected on significant progress in 2025, advancing its lead candidate, CMND-100, for Alcohol Use Disorder treatment. Key achievements include successful Phase I/IIa clinical trials, positive safety results, and global expansion of its intellectual property portfolio. The company aims to continue its pipeline advancement and explore strategic opportunities in 2026.

    StockTitan·
    US
    CMND
    -4.62%
    StockTitan·
    US
    CMND
    -4.62%

    Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 | CMND Stock News

    Clearmind Medicine Inc. announced the successful completion of patient enrollment for the second cohort in its ongoing FDA-approved Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD). The second cohort consists of six patients recruited from three clinical sites. This follows the first cohort's positive safety and efficacy results. The trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100. Dosing for the second cohort will begin soon, with topline results expected in the coming months.

    StockTitan·
    US
    CMND
    -4.62%
    StockTitan·
    US
    CMND
    -4.62%
    © 2025 Longbridge｜Disclaimer